Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial Comparing Everolimus Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors

NCT01198158 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01198158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01198158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial Comparing Everolimus Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Terminated
Start date
September 15, 2010
Completion date
December 16, 2017
Enrollment
77 (actual)
Sites
524

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, recurrent renal cell carcinoma, stage iii renal cell cancer ajcc v7, stage iv renal cell cancer ajcc v7